================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report: October 20, 2005
Date of earliest event reported: October 20, 2005
PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware 1-3619 13-5315170
(State or other jurisdiction (Commission File (I.R.S. Employer
of incorporation) (Number) Identification No.)
235 East 42nd Street 10017
New York, New York (Zip Code)
(Address of principal executive offices)
Registrant's telephone number, including area code:
(212) 573-2323
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the obligation of the registrant under any of the
following provisions:
[ ] Written communication pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2{b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
Item 2.02 Results of Operations and Financial Condition
On October 20, 2005, Pfizer Inc. (the "Company" or "Pfizer") issued a press
release announcing its financial results for the third quarter of 2005. The
information contained in the press release is deemed to be "filed" under the
Securities Exchange Act of 1934 as Exhibit 99.1 to this report, and such press
release is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(c) Exhibits
Exhibit 99.1 - Press Release of Pfizer Inc. dated October 20, 2005, reporting
Pfizer's financial results for the third quarter of 2005.
Exhibit 99.1 is deemed to be "filed" under the Securities
Exchange Act of 1934 in this Current Report on Form 8-K.
SIGNATURE
Under the requirements of the Securities Exchange Act of 1934, the registrant
has caused this report to be signed on its behalf by the authorized undersigned.
PFIZER INC.
By: /s/ Margaret M. Foran
-------------------------------
Margaret M. Foran
Title: Senior Vice President-Corporate
Governance, Associate General
Counsel and Secretary
Dated: October 20, 2005
EXHIBIT INDEX
Exhibit No. Description
----------- --------------------------------------------------------------
99.1 Press Release of Pfizer Inc. dated October 20, 2005, reporting
Pfizer's financial results for the third quarter of 2005.